Business
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
US veterans and eligible family members now have access to blood test for colorectal cancer screening with no copay Benefit will cover all eligible
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nUS veterans and eligible family members now have access to blood test for colorectal cancer screening with no copay\n\n\nBenefit will cover all eligible individuals ages 45-84, representing first coverage beyond Medicare population for Shield\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older.\n\nFollowing Medicare coverage for Shield in August 2024, the VA network coverage is the first for individuals between the ages of 45 and 64. The U.S. Department of Veterans Affairs (VA) Community Care Network (CCN) consists of community-based practitioners who provide veterans with healthcare services and covers approximately 9.1 million beneficiaries.1\n\n“We are proud of the lifesaving value that the Shield blood test can bring to U.S. veterans and their families,” said AmirAli Talasaz, Guardant Health co-CEO. “This coverage decision by the VA is the first for younger and non-Medicare beneficiaries and we are excited to broaden the impact of our screening test to help detect more colorectal cancer early, when it is most treatable.”\n\nThe U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening, and the Centers for Medicare & Medicaid Services (CMS) recently approved Advanced Diagnostic Laboratory Test (ADLT) status for Shield for colorectal cancer screening.\n\nThe Shield blood test is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit www.ShieldCancerScreen.com.\n\nAbout Guardant Health\n\nGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blo...